| 词条 | Sapanisertib |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = 5-(4-Amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine | image = Sapanisertib.svg | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1224844-38-5 | class = | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = 45375953 | DrugBank = | KEGG = D11183 | C=15|H=15|N=7|O=1 | StdInChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19) | StdInChIKey=GYLDXIAOMVERTK-UHFFFAOYSA-N | smiles = CC(C)N1C2=C(C(=N1)C3=CC4=C(C=C3)OC(=N4)N)C(=NC=N2)N }}Sapanisertib is an experimental small molecule inhibitor of mTOR. It is in development by Millennium Pharmaceuticals.[1] It is in phase II clinical trials for breast cancer, endometrial cancer, glioblastoma, renal cell carcinoma, and thyroid cancer.[2] References1. ^https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fsapanisertib.pdf 2. ^http://adisinsight.springer.com/drugs/800030541 4 : Experimental cancer drugs|Benzoxazoles|Isopropyl compounds|Amines |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。